SuperworthSarepta Therapeutics SRPT
- Market cap
- $1.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2B
- −20% on a year ago
- Net margin
- −6.9%
- Free cash flow yield
- n/m
- not a meaningful number
Sarepta Therapeutics trades at 0.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2B over the last twelve months, down 20% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $331.8M+44% | $396.8M+54% | $413.5M+63% | $362.9M+39% | $467.2M+41% | $658.4M+66% | $744.9M+80% | $611.1M+68% | $399.4M−15% | $442.9M−33% | $730.8M−2% | $401.3M−34% | |
| Cost of revenue | $37M−7% | $44.2M+43% | $50.6M+44% | $44.5M+31% | $91.7M+148% | $132.3M+200% | $137.6M+172% | $152.6M+243% | $150.8M+64% | n/a | $108.8M−21% | $149.4M−2% |
| Gross profit | $294.8M+55% | $352.6M+55% | $362.9M+66% | $318.4M+40% | $375.5M+27% | $526.1M+49% | $607.3M+67% | $458.5M+44% | $248.6M−34% | n/a | $622M+2% | $251.9M−45% |
| R&D | $194.3M−10% | $195.5M−9% | $200.4M−18% | $179.7M−26% | $224.5M+16% | $200M+2% | $773.4M+286% | $204.4M+14% | $218.9M−3% | n/a | $154M−80% | $91.3M−55% |
| SG&A | $120.9M+15% | $131.7M+9% | $127M+15% | $138.8M+17% | $128.2M+6% | $163.9M+24% | $133.6M+5% | $137.9M−1% | $91.9M−28% | n/a | $109M−19% | $107.6M−22% |
| −$20.8M−84% | $24.6M | $34.9M | −$701K−100% | $22.2M | $161.7M+557% | −$300.4M | $115.6M | −$103.4M | n/a | $358.4M | $13.3M−89% | |
| Interest expense | $5.2M−65% | $5.2M−22% | $4.2M−34% | $4.8M−8% | $4.9M−6% | $4.5M−15% | $4.5M+8% | $5.2M+8% | $7.6M+54% | n/a | $21.7M+382% | $21.5M+311% |
| Pre-tax income | −$33.2M−87% | $40.4M | $41.4M | $13.6M | $34M | $171.7M+325% | −$383.5M | $153.6M+1032% | −$194M | n/a | $343.2M | −$1.7M |
| $7.8M+488% | −$5.3M | $5.3M+32% | $7.1M−24% | $395K−95% | $12.7M | $64M+1101% | −$43.3M | −$14.1M | n/a | $12.2M−81% | $3.1M | |
| Net income | −$40.9M−84% | $45.7M | $36.1M | $6.5M | $33.6M | $159M+248% | −$447.5M | $196.9M+2948% | −$50.6M | −$412.2M | $331M | −$4.9M |
| −$0.46−84% | $0.44 | $0.37 | $0.07 | $0.34 | $1.20+173% | −$4.60 | $1.89+2600% | −$1.80 | −$3.93 | $2.88 | −$0.05 | |
| 88.9M+1% | 103.6M+18% | 99.1M+12% | 99.1M+12% | 100.4M+13% | 132.6M+28% | 97.4M−2% | 106.6M+8% | 100.2M−0% | n/a | 121.9M+25% | 105.4M−1% |
Gross profit: 37 periods, Q1 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY10 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY10 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SRPTSarepta Therapeutics | $1.9B | n/m | 99.6× | 0.9× | −20% | −6.9% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| Peer median | $1.6B | 14.1× | 17.9× | 1.8× | +6% | 10.9% |
More on Sarepta Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .